Severe PPH (≥ 1000 mL) · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids may leads to lower estimated or measured blood loss of at least 1000 mL visual estimation compared with no uterotonic agents (low certainty).
1 finding from 1 review
Haemoglobin (g/dL) · women in the third stage of labour
1 finding from 1 review
Use of therapeutic uterotonics · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids may leads to lower use of therapeutic uterotonics compared with no uterotonic agents (low certainty).
1 finding from 1 review
Elevation of blood pressure · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids may leads to higher elevation of blood pressure compared with no uterotonic agents (low certainty).
1 finding from 1 review
Pain after birth requiring analgesia (not prespecified) · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids probably leads to higher pain after birth requiring analgesia (not prespecified) compared with no uterotonic agents (moderate certainty).
1 finding from 1 review
Mean blood loss (mL) visual estimation · women in the third stage of labour
1 finding from 1 review
Maternal blood loss of 500 mL or greater · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids may leads to lower estimated or measured blood loss of at least 500 mL visual estimation compared with no uterotonic agents (low certainty).
1 finding from 1 review
Seizure cessation: within 10 minutes · Children with acute tonic‐clonic seizures
Summary of findings ‐ Intravenous lorazepam showed no clear difference in seizure cessation: within 10 minutes compared with intranasal lorazepam (moderate certainty).
1 finding from 1 review
Time from drug administration to stopping of seizures · Children with acute tonic‐clonic seizures
1 finding from 1 review
Incidence of respiratory depression · Children with acute tonic‐clonic seizures
1 finding from 1 review
Additional drugs required to stop the seizure · Children with acute tonic‐clonic seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Seizure recurrence within 24 hours · Children with acute tonic‐clonic seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of admissions to the ICU · Children with acute tonic‐clonic seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality after discharge (1‐3 months) · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in mortality after discharge (1‐3 months) compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Length of hospitalisation (days) · exacerbations of COPD
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Arterial blood gas tension: PaO2 after 3 months mmHg · exacerbations of COPD
1 finding from 1 review
Treatment failure Need for additional treatment · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in treatment failure Need to intensify therapy compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Relapse Hospital readmission for COPD · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in relapse Hospital readmission for COPD compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review